• Home
  • Investor Overview & Financial Information

Investor Overview & Financial Information

Aspira is Transforming Women's Health

with Innovative Solutions

Investor News

View More

  • Aspira Women’s Health Executes an Agreement with Axia Women’s Health to Launch Aspira Synergy Genetics Platform

    Press Release

    Read More
  • Aspira Women’s Health Inc. to Report Third Quarter 2021 Financial Results on November 10

    Press Release

    Read More
  • Genoox and Aspira Women’s Health Inc. Partner to Develop and Deliver Data-Driven Insights to Advance Women’s Health

    Press Release

    Read More

Aspira is led by an experienced team of business, medical and scientific professionals with a passion for improving health outcomes for women.

Meet our Leadership Team

About Aspira Women's Health

Our Mission

Aspira Women's Health is helping transform women’s health with the discovery, development, and utilization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. Our FDA-cleared products OVA1® and OVERA® detect the risk of ovarian malignancy in women with adnexal masses. Recently launched, Aspira GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of experience in ovarian cancer risk assessment, Aspira Women's Health has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans.

Learn More

Investor Presentations

Transforming the State of Women’s Gynecological Health …starting with Ovarian Cancer
Corporate Presentation May 2022

Investor Resources & Financial Information

Click a tab below to view more information

Investor Relations Group Image

Investor Relations

Ashley R. Robinson,
LifeSci Advisors LLC.
Tel: 617.430.7577
Email: [email protected]

Corporate Governance

Committee Members

Below is a summary of our committee membership information.

Audit CommitteeCompensation CommitteeNomination and Corporate Governance Committee
James T. LaFrance (Lead Independent Director)ChairpersonMemberChairperson
Valerie Palmieri (Executive Chairwoman)
Veronica G.H. Jordan, Ph.D.MemberChairperson
Nicole Sandford
Celeste R. Fralick, Ph.D.MemberMember

Analyst Coverage

Aspira Women's Health is followed by the analysts listed to the right. Please note that any opinions, estimates or forecasts regarding Aspira Women's Health’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Aspira Women's Health or its management. Aspira Women's Health does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.


  • William Blair & Company
  • Cantor Fitzgerald
  • Truist Securities, Inc

Webcasts and Presentations

Transforming the State of Women’s Gynecological Health …starting with Ovarian Cancer
Corporate Presentation | May 2022

Aspira Women’s Health, Inc. to Report 2021 Financial Results

Wednesday, March 23rd at 8:30 am ET


Aspira Women’s Health, Black Women's Health Imperative Lead Congressional Briefing

September 27, 2021

Click here watch the replay

SEC Filings

Annual Reports

Contact us to learn more or to speak with investor relations.